Van Leeuwenhoeck Issues Updated Addex Equity Research Report
July 20 2020 - 12:00AM
Geneva, Switzerland, July 20,
2020 – Addex Therapeutics (SIX: ADXN), a leading company
pioneering allosteric modulation-based drug discovery and
development today announced that the independent life science
equity research company, Van Leeuwenhoeck, has issued an equity
research report highlighting the Addex investment opportunity and a
valuation of CHF13-14 per share. Analyses in the report notes a
significant undervaluation of Addex, which is trading currently at
CHF1.40 per share, as well as key near term value drivers including
the start of a pivotal registration study of dipraglurant for
levodopa-induced dyskinesia associated with Parkinson’s disease and
the recently announced decision of Addex partner Janssen
Pharmaceuticals Inc., to advance ADX71149 into a Phase 2a proof of
concept study in epilepsy.
“We believe Addex is fundamentally undervalued
and the start of pivotal registration studies in PD-LID as well as
positive news flow from its other in-house discovered programs is
likely to drive significant share price appreciation in the coming
12 months,” commented Marcel Wijma, Chief Research Analyst at Van
Leeuwenhoeck Institute. “Added to this, Addex has a leading
position in allosteric modulation and a broad pipeline, which
provides significant value inflection points in the medium to long
term.”
The full analyst research report is available on
www.leeuwenhoeck.com and on Addex website at
https://www.addextherapeutics.com/en/investors/downloads/.
About Van Leeuwenhoeck Research and their
research report
Van Leeuwenhoeck Institute, (“VLI”) is actively
engaged in the financial research of life sciences companies in
Europe, North America, Australia and emerging markets such as Asia
and India. The VLI team conducts fundamental financial research,
independently from any specific broker, bank, or investor. A select
circle of top analysts assists the firm in conducting fundamental
biotech research according to the highest standards. The team’s
sector expertise, combined with an active network of well-respected
scientists and biotech business analysts, adds value to VLI’s
research. VLI provides institutional investors and other
professional investors with independent, un-biased research on the
real value of innovative Life Sciences companies.
About Addex Therapeutics
Addex Therapeutics is a clinical-stage
pharmaceutical company focused on the development and
commercialization of an emerging class of novel orally available
small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex's
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex's lead drug candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is scheduled to enter a
pivotal registration clinical trial for Parkinson’s disease
levodopa induced dyskinesia (PD-LID). In parallel, dipraglurant's
therapeutic use in dystonia is being investigated in preclinical
models. Addex's second clinical program, ADX71149 (mGlu2 positive
allosteric modulator or PAM) is being developed in collaboration
with Janssen Pharmaceuticals, Inc for the treatment of epilepsy. In
addition, Addex’s GABAB PAM program has been licensed to
Indivior PLC for the treatment of addiction. Preclinical programs
include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for
mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease
and mGlu3 PAM for neurodegenerative
disorders.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55Email:
PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Disclaimer / Forward-looking
statements: This communication does not constitute an
offer or invitation to subscribe for or purchase any securities of
Addex Therapeutics Ltd. This publication may contain certain
forward-looking statements concerning the Company and its business.
Such statements involve certain risks, uncertainties and other
factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially
different from those expressed or implied by such statements.
Readers should therefore not place undue reliance on these
statements, particularly not in connection with any contract or
investment decision. The Company disclaims any obligation to update
these forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Apr 2024 to May 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From May 2023 to May 2024